Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.
JSON
Simpson-Yap S, Pirmani A, De Brouwer E, Peeters LM, Geys L, Parciak T, Helme A, Hillert J, Moreau Y, Edan G, Spelman T, Sharmin S, McBurney R, Schmidt H, Bergmann A, Braune S, Stahmann A, Middleton R, Salter A, Bebo B, van der Walt A, Butzkueven H, Ozakbas S, Karabudak R, Boz C, Alroughani R, Rojas JI, van der Mei I, Sciascia do Olival G, Magyari M, Alonso R, Nicholas R, Chertcoff A, Zabalza A, Arrambide G, Nag N, Descamps A, Costers L, Dobson R, Miller A, Rodrigues P, Prčkovska V, Comi G, Kalincik T
Mult Scler Relat Disord 66 (-) 104072 [2022-10-00; online 2022-07-25]
Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.
PubMed 35917745
DOI 10.1016/j.msard.2022.104072
Crossref 10.1016/j.msard.2022.104072
pmc: PMC9310378
pii: S2211-0348(22)00580-6